copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | Harrow, Inc. Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
Harrow Announces First-Quarter 2025 Financial Results Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
SEC Filings | Harrow, Inc. The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
Corporate Presentation November 2025 - harrow. com Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
Careers | Harrow, Inc. At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where initiative is celebrated, creativity thrives, and impact is real
Quarterly Results | Harrow, Inc. The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
www. harrow. com harrow health inc-2 harrow health inc-1 harrow health inc Harrow Health INC 2,145,767 shares of common stock available for award under the Company’s 2017 Incentive Stock and Awards Plan (the “Plan) as of March 31, 2023;
www. harrow. com much more Market Expansion Strategy: Build on Harrow’s established ophthalmic footprint to drive adoption initially in cataract and other ophthalmic procedures, followed by expansion into additional outpatient and in-office settings where opioid-free, needle-free sedation can improve patient experience and workflow efficiency